Fig. 6From: Belgian rare diseases plan in clinical pathology: identification of key biochemical diagnostic tests and establishment of reference laboratories and financing conditionsSignificant impact of the feasibility study results on the annual volumes of six analyses. Comparison of the volumes of tests reported by the Belgian laboratories of clinical pathology for 6 different years: group A (light grey bars, period before the presentation of the results of the feasibility study [data collected for 2014 and 2015]) versus group B (dark grey bars, period after the presentation of the results of the feasibility study [data collected for 2016 and 2017]) versus group C (black bars, period from RLs’ recognition [data collected for 2019 and 2020]). Values were calculated as mean volumes ± SD, n = 2 for the 3 groups (A,B,C) of two successive years. Statistical analyses were performed by one-way ANOVA with Tukey’s posttest for multiple comparisons between the 3 groups. Asterisks indicate values that are statistically significantly different from each other (*p < 0.05). Analyses presented in each panel: a assessment of α-aminoadipic semialdehyde and δ1-piperideine-6-carboxylate in urine; b assessment of B6 vitamers in plasma; c assessment of pterins in urine; d assessment of Complement component Factor B; e assessment of Complement component Factor Bb; f assessment of intra-leukocyte cystine. RLs Reference laboratoriesBack to article page